Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 16/20 | 0.79 |
| ▸ | GABRB3 | P28472 | 16/20 | 0.79 |
| ▸ | GABRA3 | P34903 | 12/20 | 0.79 |
| ▸ | GABRA5 | P31644 | 14/20 | 0.63 |
| ▸ | GABRA1 | P14867 | 10/20 | 0.63 |
| ▸ | GABRA2 | P47869 | 10/20 | 0.63 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.63 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.63 |
| ▸ | GABRB2 | P47870 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16063039 | 0.91 | GABRG2 (0.83) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL2838589 | 0.90 | GABRG2 (0.81) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL29712005 | 0.89 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL29518128 | 0.89 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL7721750 | 0.89 | GABRG2 (1.00) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL14186978 | 0.88 | GABRG2 (0.77) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL2845958 | 0.84 | GABRG2 (0.77) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL30730005 | 0.84 | GABRG2 (0.77) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL13523833 | 0.83 | GABRG2 (0.69) | GABRG2GABRB3GABRA3GABRA5GABRA1 | |
| SCHEMBL8359220 | 0.83 | GABRG2 (0.76) | GABRG2GABRB3GABRA3GABRA5GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235656-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | GABRA3, GABRA6, GABRA4 | GABRG2 14/4885GABRB3 8/4885GABRA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.